[Federal Register Volume 87, Number 18 (Thursday, January 27, 2022)]
[Notices]
[Pages 4259-4260]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-01550]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and/or contract proposals 
and the discussions could disclose confidential trade secrets or 
commercial property such as patentable material, and personal 
information concerning individuals associated with the grant 
applications and/or contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Exploiting Genome or Epigenome Editing to 
Functionally Validate Genes or Variants Involved in Substance Use 
Disorders (R21/R33 Clinical Trial Not Allowed).
    Date: February 14, 2022.
    Time: 11:00 a.m. to 1:30 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute on Drug Abuse/NIH, National Institute 
on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 
(Virtual Meeting).
    Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, 301 
North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-
4471, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Avenir Award Program for Genetics or Epigenetics of 
Substance Use Disorders (DP1 Clinical Trial Optional).
    Date: February 23-24, 2022.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, 301 
North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-
4471, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Device-Based Treatments for Substance Use Disorders 
(UG3/UH3, Clinical Trial Optional).
    Date: March 2, 2022.
    Time: 10:00 a.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Preethy Nayar, Ph.D., Scientific Review Officer, 
Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 
North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, 301-443-
4577, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; NIDA Centers Review.
    Date: March 3, 2022.
    Time: 10:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Trinh T. Tran, Ph.D., Scientific Review Officer, 
Office of Extramural Policy and Review, Division of Extramural 
Research, National Institute on Drug Abuse, NIH, 301 North 
Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-5843, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; PrEP for HIV Prevention among Substance Using 
Populations (R01--Clinical Trial Optional).
    Date: March 7, 2022.
    Time: 10:00 a.m. to 1:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Rebekah Feng, Ph.D., Scientific Review Officer, 
Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 
North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-
7245, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; HEAL Initiative: Novel Targets for Opioid Use 
Disorders and Opioid Overdose.
    Date: March 8-9, 2022.
    Time: 10:00 a.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, 301 
North Stonestreet

[[Page 4260]]

Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-4471, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: January 21, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-01550 Filed 1-26-22; 8:45 am]
BILLING CODE 4140-01-P